TriSalus Life Sciences® Inc., an oncology company specializing in novel delivery technologies combined with immunotherapy for liver and pancreatic tumors, showcased its groundbreaking technology through two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting. The presentations highlighted the promising developments of the TriSalus Infusion System and its Pressure-Enabled Drug Delivery™ (PEDD™) method in clinical trials and retrospective studies for treating various tumor types.
In the Phase 1/1b PERIO-03 trial, TriSalus examined the delivery of nelitolimod (formerly SD-101), a class C toll-like receptor-9 (TLR9) agonist, in patients with locally advanced pancreatic adenocarcinoma. The treatment, administered using the PEDD method with the TriSalus Infusion System through a retrograde venous approach, yielded encouraging early safety and feasibility data. All five patients treated demonstrated technical success, with no immediate procedural complications or evidence of hemorrhage or thrombosis. This trial, part of TriSalus’s broader effort to harness PEDD for enhanced therapeutic delivery, indicated promising immune responses within the treated pancreatic tumors, aligning to improve patient outcomes.
Additionally, a retrospective clinical study from The University of Texas MD Anderson Cancer Center focused on using the TriNav microcatheter to embolize hypovascular solid tumors, including those in the liver, bone, and adrenal gland. The study reported a 100% technical success rate, showcasing the effectiveness of the PEDD method in treating tumors typically challenging for embolization. Local tumor progression-free survival rates highlighted the potential of this technology to impact patient care significantly.
These findings underscore TriSalus’s commitment to leveraging novel drug delivery technologies to overcome the challenges of solid tumor treatments, particularly in liver and pancreas cancers. Steven C. Katz, M.D., FACS, Chief Medical Officer at TriSalus, emphasized the potential of the PEDD method to enhance therapeutic uptake and clinical outcomes across various disease sites. The successful integration of such innovative technologies into clinical practice, supported by the Centers for Medicare & Medicaid Services’ recent reimbursement code for procedures involving the TriNav system, marks a significant advancement in treating cancer patients.
The Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials continue to explore the utility of delivering investigational treatments like nelitolimod via TriSalus’s proprietary technology, underscoring the company’s dedication to advancing precision medicine and improving the lives of those affected by cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.